Tempus AI (TEM) and Predicta Biosciences announced the commercial expansion of a co-branded whole-genome sequencing, WGS, assay, currently known as GenoPredicta, intended for the comprehensive genomic characterization of hematologic malignancies and measurable residual disease, MRD, monitoring. “GenoPredicta offers a novel, unified solution for our life science partners and a comprehensive replacement for traditional, siloed testing,” said Kate Sasser, PhD, Chief Scientific Officer at Tempus. “By consolidating flow cytometry, cytogenetics, and WGS into one ultrasensitive workflow, we can identify high-risk biomarkers and track clonal evolution from as few as 50 tumor cells. Crucially, because the assay delivers 100% concordance between peripheral blood and bone marrow, it can provide these deep insights while sparing patients from biopsies.”
Claim 55% Off TipRanks
Forget margin or options. Here's how the pros trade TEMPublished first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TEM:
- Tempus AI announces 31 abstracts for presentation at AACR annual meeting
- tempus AI Inc Class A call volume above normal and directionally bullish
- AI Daily: OpenAI touts Amazon alliance in memo
- Nike downgraded, Starbucks upgraded: Wall Street’s top analyst calls
- Tempus AI launches automated ‘Active Follow-Up’ service